US 12,435,119 B2
Genetically engineered cell and application thereof
Zonghai Li, Shanghai (CN); Hong Luo, Shanghai (CN); Hua Jiang, Shanghai (CN); and Huamao Wang, Shanghai (CN)
Assigned to CRAGE Medical Co., Limited, Hong Kong (CN)
Appl. No. 17/055,470
Filed by CRAGE medical Co., Limited, Hong Kong (CN)
PCT Filed May 15, 2019, PCT No. PCT/CN2019/087077
§ 371(c)(1), (2) Date Nov. 13, 2020,
PCT Pub. No. WO2019/219029, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 201810463564.7 (CN), filed on May 15, 2018; application No. 201811088090.9 (CN), filed on Sep. 18, 2018; application No. 201811552806.6 (CN), filed on Dec. 19, 2018; and application No. 201910151930.X (CN), filed on Feb. 28, 2019.
Prior Publication US 2021/0213061 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 14/54 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)
CPC C07K 14/70517 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 14/5418 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/28 (2013.01); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 15/86 (2013.01); A61K 2239/28 (2023.05); A61K 2239/38 (2023.05); A61K 2239/49 (2023.05); A61K 2239/53 (2023.05); A61K 2239/54 (2023.05); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2830/002 (2013.01)] 38 Claims
 
1. A genetically engineered T cell, wherein the cell expresses an exogenous receptor specifically binding to a target antigen, an-exogenous CCL21, a protein promoting the proliferation of the cell, which is an exogenous IL-7, and wherein the cell does not express an exogenous CCL19.